GSK (NYSE: GSK) executives acquire small share awards under plan

Rhea-AI Filing Summary

GSK plc reported a series of small share acquisitions by senior executives under the company’s Share Reward Plan. On 9 December 2025, Chief Executive Officer Emma Walmsley, Chief Financial Officer Julie Brown and several other senior leaders, including the group general counsel, heads of global communications, corporate development, global supply chain, global affairs, ViiV Healthcare and the company secretary, each acquired GSK ordinary shares of 31¼ pence. The purchases combined partnership and matching shares, with individual totals ranging from 12 to 14 ordinary shares at a price of £18.0780 per share. All transactions took place on the London Stock Exchange (XLON) and are routine disclosures of dealings by persons discharging managerial responsibilities.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Emma Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.0780	7 (partnership shares)
		£18.0780	7 (matching shares)
d)	Aggregated information Aggregated volume Price	14 Ordinary Shares £18.0780
e)	Date of the transaction	2025-12-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Julie Brown
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.0780	6 (partnership shares)
		£18.0780	6 (matching shares)
d)	Aggregated information Aggregated volume Price	12 Ordinary Shares £18.0780
e)	Date of the transaction	2025-12-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.0780	6 (partnership shares)
		£18.0780	6 (matching shares)
d)	Aggregated information Aggregated volume Price	12 Ordinary Shares £18.0780
e)	Date of the transaction	2025-12-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.0780	7 (partnership shares)
		£18.0780	7 (matching shares)
d)	Aggregated information Aggregated volume Price	14 Ordinary Shares £18.0780
e)	Date of the transaction	2025-12-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President, Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.0780	7 (partnership shares)
		£18.0780	7 (matching shares)
d)	Aggregated information Aggregated volume Price	14 Ordinary Shares £18.0780
e)	Date of the transaction	2025-12-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Regis Simard
b)	Position/status	President, Global Supply Chain
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.0780	7 (partnership shares)
		£18.0780	7 (matching shares)
d)	Aggregated information Aggregated volume Price	14 Ordinary Shares £18.0780
e)	Date of the transaction	2025-12-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Philip Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.0780	7 (partnership shares)
		£18.0780	7 (matching shares)
d)	Aggregated information Aggregated volume Price	14 Ordinary Shares £18.0780
e)	Date of the transaction	2025-12-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Deborah Waterhouse
b)	Position/status	CEO, ViiV Healthcare and President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.0780	7 (partnership shares)
		£18.0780	7 (matching shares)
d)	Aggregated information Aggregated volume Price	14 Ordinary Shares £18.0780
e)	Date of the transaction	2025-12-09
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Victoria Whyte
b)	Position/status	SVP & Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£18.0780	7 (partnership shares)
		£18.0780	7 (matching shares)
d)	Aggregated information Aggregated volume Price	14 Ordinary Shares £18.0780
e)	Date of the transaction	2025-12-09
f)	Place of the transaction	London Stock Exchange (XLON)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: December 11, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What did GSK (GSK) disclose in this Form 6-K filing?

GSK disclosed that several senior executives acquired small numbers of ordinary shares under the company’s Share Reward Plan and reported the details as required for persons discharging managerial responsibilities.

Which GSK executives bought shares and in what size?

Executives including CEO Emma Walmsley, CFO Julie Brown, and senior leaders such as James Ford, Sally Jackson, David Redfern, Regis Simard, Philip Thomson, Deborah Waterhouse and Victoria Whyte each acquired between 12 and 14 ordinary shares through partnership and matching awards.

At what price were the GSK shares acquired in the Share Reward Plan?

The disclosed acquisitions were made at a price of £18.0780 per ordinary share for both partnership and matching shares under the Share Reward Plan.

When and where did these GSK executive share transactions occur?

The transactions took place on 9 December 2025 and were executed on the London Stock Exchange (XLON), involving GSK ordinary shares of 31¼ pence each.

What is the nature of GSK’s Share Reward Plan mentioned in the filing?

The Share Reward Plan is an arrangement under which GSK executives acquire partnership shares and receive matching shares, leading to periodic small acquisitions of GSK ordinary shares that must be reported as transactions by senior management.

Does this GSK filing indicate a major change in ownership or capital structure?

No. The filing reports small routine acquisitions of GSK ordinary shares by several executives, with individual totals of 12 to 14 shares, and does not describe any broader change to GSK’s capital structure.